Rocket Pharmaceuticals (RCKT) PT Raised to $15 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Price: $2.31 -6.85%
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 33
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 33
Join SI Premium – FREE
Cantor Fitzgerald analyst Josh Schimmer raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $15.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fastenal (FAST) PT Raised to $51 at DA Davidson
- LVMH (MC:FP) (LVMUY) PT Lowered to EUR425 at TD Cowen
- 10X Genomics (TXG) PT Raised to $70 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
